Abstracts

Growth Differences in Infants Born To Perinatally vs. Non-Perinatally HIV-Infected Women

Background: Pregnancy & infant growth outcomes are not well documented in perinatally HIV+ (PHIV) women & their children. We evaluate growth to 1 year in infants of PHIV vs. non-perinatally HIV+ (NPHIV) women. Methodology: Using routinely collected weight, length, & head circumference data, we evaluated weight-for-age (WAZ), length-for-age (LAZ), weightfor-length (WFLZ), & head circumference-for-age (HCAZ)…

Concentrations of Nevirapine or Efavirenz on and off Anti-tuberculosis Therapy (ANRS12214)

Background: The randomized ANRS12146-CARINEMO clinical trial enrolled Mozambican HIV-tuberculosis (TB) coinfected patients with the objective to compare efficacy and tolerance of nevirapine (NVP) or efavirenz (EFV)-based antiretroviral (ARV) therapy. Non inferiority of NVP could not be demonstrated. A substudy was designed to compare concentrations (conc.) of NVP or EFV during coadministration with TB treatment and…

No Meaningful PK Interaction Between HCV Protease Inhibitor MK-5172 and Tenofovir or Raltegravir

Background: MK-5172 is a potent, once-daily inhibitor of the hepatitis C virus (HCV) NS3/4A protease that is being developed for the treatment of chronic HCV infection in mono- and HCV/human immunodeficiency virus (HIV)-coinfected patients. The present study evaluated the pharmacokinetic interactions and tolerability of MK-5172 coadministered either with tenofovir (TDF, HIV NRTI) or raltegravir (RAL,…

No Clinically Relevant Interactions Between Daclatasvir and Cyclosporine or Tacrolimus

Background: Chronic HCV infection is the main cause of liver transplantation (LT). HCV recurrence, seen in ≈50% of HCV-infected LT patients during the first postoperative year, is the main cause of graft failure (despite long-term treatment with immunosuppressants eg cyclosporine [CSP] or tacrolimus [TAC]) and death in HCV-infected LT patients. Drug-drug interactions (DDIs) with CSP…

Effect of Faldaprevir on Atazanavir Pharmacokinetics in Patients With HIV/HCV Coinfection*

Background: Faldaprevir (FDV) is a potent, once-daily HCV NS3/4A protease inhibitor being developed for the treatment of chronic HCV infection in monoinfected patients and those co-infected with HIV. In healthy subjects, FDV had no clinically relevant effect on the exposure of tenofovir, darunavir, raltegravir, and efavirenz. The objective of this substudy of STARTVerso4 was to…

Impact of Randomized Antiretroviral Therapy (ART) Initiation on Glucose Metabolism: ACTG A5224s

Background: Prior studies have found that early HIV protease inhibitors (PIs) and lipodystrophy contribute to glucose dysregulation. Few randomized trials have evaluated glucose indices in ART-naive subjects on newer ARTs. Methodology: A5202 randomized 1857 ART-naive HIV+ subjects to blinded abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) with open-label efavirenz (EFV) or atazanavir/ritonavir (ATV/r). A pre-specified secondary analysis…

Triglycerides/HDL Ratio and Risk of DevelopingDiabetes Mellitus During Antiretroviral Therapy

Background: The aim of our analysis was to evaluate the incidence of diabetes mellitus (DM) and its association with triglycerides (TRG), triglycerides to high-density lipoprotein cholesterol ratio (TRG/HDL) and liver fibrosis (measured by FIB-4) during combination antiretroviral therapy (cART). Methodology: Patients from the ICONA Foundation study initiating first-line cART between 1997 and 2013 were selected…